About us

Our leadership team has experience in managing both small and large public and private companies through various stages of growth and financing strategies (venture capital, M&A transactions, IPOs, PIPEs).

They successfully sold the surface modification business of Interface Biologics to Evonik (ETR:EVK) in 2019 and founded Ripple Therapeutics in January of 2020.

Ripple Therapeutics

Ripple Therapeutics is a privately held ophthalmic clinical stage biotech company that designs drug delivery implants.

Ripple’s patented technology platform simplifies treatment for patients with glaucoma, retina disease and other causes of blindness, by eliminating the need for daily drops or monthly injections.

The technology is based on a discovery that drugs can be chemically engineered into controlled release pharmaceuticals without the use of polymers or excipients, meaning once the drug is gone, the implant is gone without any inflammatory degradation products. These “prodrugs” are highly customized to tailor both the drug dose and duration, resulting in an improved safety profile, extended therapeutic benefit and reduced treatment burden for both the patient and their physician.

In 2021 the first Retina patients with RVO and DME were treated with IBE-814, Ripple’s Dexamethasone IVT implant in the RIPPLE-1 clinical trial, demonstrating safety, efficacy and duration.

In 2022, Ripple’s Glaucoma implant’s pre-clinical data confirmed safety and efficacy. Later, a dosing study established long-term safety after a second implant is administered.

Ripple recently announced a collaboration and option-to-license agreement with AbbVie (NYSE:ABBV) to develop a next generation, fully biodegradable, sustained release drug delivery implant with potential repeat dosing capabilities to reduce intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. This collaboration leverages AbbVie’s expertise in eye care and Ripple’s innovative drug delivery platform, with the potential to deliver a meaningful impact on the lives of people living with glaucoma. Under terms of this agreement, Ripple received an upfront payment of $21.8M USD and is eligible to receive up to $290M USD in aggregate option fees and milestones, as well as tiered royalties on net sales.

Additionally, Ripple announced evaluation and licensing agreement with Glaukos (NYSE: GKOS).

Ripple is expanding its proprietary pipeline to include Dry AMD and Geographic Atrophy.